Clinical trials: Metastatic Colorectal Cancer, completed
Colorectal Cancer, Neoplasm Metastasis
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
This is a Phase II, open label, non-randomized study in subjects with histologically confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who have not received prior chemotherapy for metastatic…
- Trial name
- NCT00444678
- Testing
- Cetuximab, Oxaliplatin, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- NYU Langone Health
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Metastatic Colorectal Adenocarcinoma
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC).
- Trial name
- NCT03043313
- Testing
- Trastuzumab, Tucatinib
- Where
- 56 sites in United States, Belgium and 3 more
- Volunteers
- 117 people
- Sponsor
- Seagen Inc.
Colorectal Cancer, Breast Cancer
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
This is a feasibility study to look for genetic alterations in tissue and blood samples that may be useful in determining what treatments may be useful in the patient's cancer care.
- Conditions
- Colorectal Cancer, Breast Cancer, Gynecological Cancer, Metastatic
- Trial name
- NCT01703585
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
Phase II trial to study the effectiveness of combining oxaliplatin, fluorouracil and leucovorin in treating patients who have metastatic colorectal cancer that has been previously treated with irinotecan.
- Trial name
- NCT00016978
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 24 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with…
- Trial name
- NCT00003225
- Testing
- amifostine trihydrate, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colon Cancer
INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer
This proposal seeks to further understand the contribution of the PIK3CA mutations in colon cancer, by correlating the type of hotspot mutation with the development of metastases in stage II and stage Ill patients.
- Trial name
- NCT03951389
- Testing
- Non-interventional
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- New Mexico Cancer Research Alliance
Colorectal Cancer Metastatic
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
This prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF V600E-Mutant Metastatic Colorectal…
- Trial name
- NCT04790448
- Testing
- Cetuximab, Irinotecan, Vemurafenib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer
Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to 31/12/2013,) the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic…
- Trial name
- NCT01811108
- Where
- 6 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Cancer
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004252
- Testing
- fluorouracil, leucovorin calcium, semaxanib
- Where
- 26 sites in United States
- Sponsor
- Pfizer
Colorectal Cancer
S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating older patients who have…
- Trial name
- NCT00049335
- Testing
- capecitabine
- Where
- 90 sites in United States
- Volunteers
- 29 people
- Sponsor
- SWOG Cancer Research Network
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00023933
- Testing
- iodine I 131 monoclonal antibody CC49-deltaCH2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation
A multicentre two-part phase I/II study evaluating response and safety of SORAFENIB in combination with irinotecan in the second line treatment or more of metastatic colorectal cancer with K-RAS mutation.
- Trial name
- NEXIRI (NCT00989469)
- Testing
- Nexavar (Sorafenib) and irinotecan (Campto)
- Where
- 5 sites in France
- Volunteers
- 64 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study will evaluate the efficacy and safety of adding bevacizumab to crossover fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer who have experienced disease progression under first line…
- Trial name
- NCT00700102
- Testing
- Chemotherapy, Bevacizumab
- Where
- 300 sites in Austria, Belgium and 13 more
- Volunteers
- 820 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment
This is an observational study in which data already collected from people with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part…
- Trial name
- RegoSeq (NCT06137170)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 3 sites in France, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Lung Metastasis, Colorectal Cancer
Radiofrequency Ablation in Resectable Colorectal Lung Metastasis
Lung metastasectomy is the only therapeutic option to provide a long-survival in patients with colorectal lung metastases. Recent studies have shown that radiofrequency (RF) ablation is a safe and useful therapeutic option for…
- Trial name
- NCT00776399
- Testing
- Lung radiofrequency ablation
- Where
- 16 sites in Japan
- Volunteers
- 70 people
- Sponsor
- Mie University
Colorectal Neoplasms
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
This is a study to evaluate the efficacy (effectiveness) and the safety of regorafenib when given in combination with chemotherapy mFOLFOX6 as first line therapy in patients with metastatic colorectal cancer (CRC).
- Trial name
- NCT01289821
- Testing
- Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Colorectal Cancer
Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00303771
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- 77 sites in France
- Volunteers
- 282 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Metastatic Colorectal Cancer
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
This is a Phase I trial to study the safety of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer.
- Trial name
- NCT01270698
- Testing
- IMMU-130
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Gilead Sciences